{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:37:59Z","timestamp":1789907879727,"version":"4.0.1"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We evaluated the antifungal activities of amphotericin B, fluconazole, and flucytosine, alone and in combination, in a murine model of cryptococcal meningitis. The objectives were to determine the greatest antifungal effects achievable with these drugs alone or in combination. Meningitis was established in male BALB\/c mice weighing 23 to 25 g by intracerebral injection of\n            <jats:italic>Cryptococcus neoformans<\/jats:italic>\n            . Treatment was started on day 2. Amphotericin B was tested at 0.3 to 1.3 mg\/kg of body weight\/day by slow intravenous injection. Fluconazole at 10 to 40 mg\/kg\/day and flucytosine at 20 to 105 mg\/kg\/day were administered in the sole source of drinking water. The mice were killed at 16 days, and the numbers of fungal colonies in the brain were quantified. The association between the response and the dose combination was evaluated by local nonparametric response surface methods; 99% confidence intervals were used to evaluate the antifungal effects. Ninety-five percent of the mice treated with amphotericin B at 0.5 mg\/kg survived to the end of the experiment, regardless of the fluconazole or flucytosine dose used. The greatest activity was seen with amphotericin B plus fluconazole with or without flucytosine. However, the addition of flucytosine did not increase the antifungal activity. Given the widespread availability of amphotericin B and fluconazole and the relative safety profile of fluconazole compared to that of flucytosine, the full potential of this two-drug combination deserves further evaluation.\n          <\/jats:p>","DOI":"10.1128\/aac.48.3.985-991.2004","type":"journal-article","created":{"date-parts":[[2004,2,24]],"date-time":"2004-02-24T17:53:08Z","timestamp":1077645188000},"page":"985-991","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":70,"title":["Amphotericin B and Fluconazole, a Potent Combination Therapy for Cryptococcal Meningitis"],"prefix":"10.1128","volume":"48","author":[{"given":"Robert A.","family":"Larsen","sequence":"first","affiliation":[{"name":"Department of Medicine (Infectious Diseases), University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Medicine (Infectious Diseases), University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Northern Colorado, Greeley, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Richard","family":"Graybill","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1590\/S0036-46651997000600010","volume":"39","year":"1997","unstructured":"Alves, S. H., J. O. Lopes, J. M. Costa, and C. Klock. 1997. Development of secondary resistance to fluconazole in Cryptococcus neoformans isolated from a patient with AIDS. Rev. Inst. Med. Trop. Sao Paulo39:359-361.","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"e_1_3_2_3_2","first-page":"1337","volume":"23","year":"1996","unstructured":"Armengou, A. C., Porcar, J. Mascaro, and F. Garcia-Bragado. 1996. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis.23:1337-1338.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_4_2","unstructured":"Bauer M. A. M. Thomas J. R. Graybill and R. A. Larsen. 1998. Display of confidence intervals for response surfaces in combination drug experiments p. 100-105. In Proceedings of statistical graphics 1997 JSM. American Statistical Association Alexandria Va."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907193010303"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/095646249500600510"},{"key":"e_1_3_2_7_2","first-page":"165","volume":"46","year":"1997","unstructured":"Centers for Disease Control and Prevention. 1997. Update: trends in AIDS incidence. Morbid. Mortal. Wkly. Rep.46:165-173.","journal-title":"Morbid. Mortal. Wkly. Rep."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Cleveland W. S. E. Grosse and W. M. Shyu. 1991. Local regression models p. 309-376. In J. M. Chambers and T. Hastie (ed.) Statistical models in S. Chapman & Hall New York N.Y.","DOI":"10.1201\/9780203738535-8"},{"key":"e_1_3_2_9_2","unstructured":"Cleveland W. S. 1993. Visualizing data. Hobart Summit N.J."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.528"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1589"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1997.tb00231.x"},{"key":"e_1_3_2_13_2","first-page":"224","volume":"47","year":"2000","unstructured":"Ford, B. J. 2000. AIDS and Africa. Biologist47:224.","journal-title":"Biologist"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111230-00026"},{"key":"e_1_3_2_15_2","first-page":"51","volume":"45","year":"1999","unstructured":"Gangaidzo, I. T., J. Mielke, and J. A. Matenga. 1999. Ethical considerations in the care of the patient with HIV\/AIDS. Central Afr. J. Med.45:51-53.","journal-title":"Central Afr. J. Med."},{"key":"e_1_3_2_16_2","unstructured":"Greenwood M. 1926. The natural duration of cancer. In Reports of public health and medical subjects vol. 33. Her Majesty's Stationery Office London United Kingdom."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/314606"},{"key":"e_1_3_2_18_2","unstructured":"Hoaglin D. C. F. Mosteller and J. W. Tukey. 1983. Understanding robust and exploratory data analysis. John Wiley & Sons Inc. New York N.Y."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.9.2178"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199712000-00010"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1086\/340525","volume":"34","year":"2002","unstructured":"Liliang, P. C., C. L. Liang, W. N. Chang, K. Lu, and C. H. Lu. 2002. Use of ventriculoperitoneal shunts to treat uncontrollable intracranial hypertension in patients who have cryptococcal meningitis without hydrocephalus. Clin. Infect. Dis.34:E64-E68.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2307\/2530904","volume":"40","year":"1984","unstructured":"Link, C. L. 1984. Confidence intervals for the survival function using Cox's proportional hazards model with covariates. Biometrics40:601-610.","journal-title":"Biometrics"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.77.914.769"},{"key":"e_1_3_2_25_2","unstructured":"National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1086\/342299","volume":"35","year":"2002","unstructured":"Newton, P. N., H. Thai le, N. Q. Tip, J. M. Short, W. Chierakul, A. Rajanuwong, P. Pitisuttithum, S. Chasombat, B. Phonrat, W. Maek-A-Nantawat, R. Teaunadi, D. G. Lalloo, and N. J. White. 2002. A randomized, double blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin. Infect. Dis.35:769-772.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1086\/515161","volume":"28","year":"1999","unstructured":"Park, M. K., D. R. Hospenthal, and J. E. Bennett. 1999. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin. Infect. Dis.28:629-633.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/jinf.2001.0916","volume":"43","year":"2001","unstructured":"Pitisuttithum, P., S. Tansuphasawadikul, A. J. Simpson, P. A. Howe, and N. J. White. 2001. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J. Infect.43:226-233.","journal-title":"J. Infect."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/515074"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/313757"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","volume":"83","year":"1987","unstructured":"Stamm, A. M., R. B. Diasio, W. E. Dismukes, S. Shadomy, G. A. Cloud, C. A. Bowles, G. H. Karam, and A. Espinel-Ingroff. 1987. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am. J. Med.83:236-242.","journal-title":"Am. J. Med."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707033370103"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Venables W. N. and B. D. Ripley. 1999. Modern applied statistics with S-PLUS 3rd ed. Springer-Verlag Inc. New York N.Y.","DOI":"10.1007\/978-1-4757-3121-7"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.3.985-991.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.3.985-991.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:20:30Z","timestamp":1645467630000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.3.985-991.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1128\/AAC.48.3.985-991.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.3.985-991.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"2003-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}